A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD.
Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
Inclusion Criteria:
Exclusion Criteria:
amanda@transcendtherapeutics.com650-769-6472
Tucson, Arizona 85715, United States
whotz@delsolresearch.com(520) 481-8464
Cherry Hill, New Jersey 08002, United States
501-553-9987
(858) 412- 4130
mpiesman@calneuroresearch.com310-208-7144
rachelle.phillips@empathxresearch.com
jlamb@excellresearch.com760-758-2222
bshih@atpcr.com949-354-5353
caralinel@pnsoc.com949-354-5353
vanessa.montanez@inlandpsych.com909-955-5865
study@starlightclinicalresearch.com970-420-5804
904-281-5757
lrueda@segaltrials.com
ashley.thompson@accelclinical.com407-644-1165
awesterfeld@cnshealthcare.com
sschneider@uptownresearch.com
504-336-2667
surya.korn@pharmasiteresearch.com410-497-8915
rpatel@vitalixclinical.com508-723-3730
idiab@archclinicaltrials.com(314) 282-3521
lvanwinkle@midwestresearchgroup.com636-496-8032 ext. 5
jmellon@luminacrc.com856-857-9500 ext. 220
tbelleface@gminstitutes.com609-921-3555
jessica@bbhnj.com732-244-2299
matthew.turzilli@imaresearch.com(212) 595-5012
216-526-1843
610-277-8073
info@suburbanresearch.com601-891-9024
512-521-0595
auga@haracechealth.com915-200-1144
mbrams@elevateclinical.com832-240-9765
maria.castro@numinusnetwork.com
apply@innerspaceresearch.com801-871-5516
empower@seattlentc.com206-467-6300 ext. 5